The share price of Cambridge-based pharmaceutical company AstraZeneca rose in European trading on Monday after the company reconfirmed its full-year outlook following second-quarter results that beat analyst expectations.
Net profit climbed more than 2% to $2.51 billion (€2.2bn) in the three months to the end of June compared with the same period last year, driven by continued strong growth in sales of its cancer medicines.